CorMedix Inc
CRMD7.090USD
+0.030+0.42%
Close 01/14, 16:00（ET）Quotes delayed by 15 min
555.49MMarket Cap
2.99P/E TTM
More Details of CorMedix Inc Company
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
CorMedix Inc Info
Ticker SymbolCRMD
Company nameCorMedix Inc
IPO dateMar 25, 2010
CEOTodisco (Joseph)
Number of employees64
Security typeOrdinary Share
Fiscal year-endMar 25
Address300 Connell Drive
CityBERKELEY HEIGHTS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07922
Phone19085179500
Websitehttps://cormedix.com/
Ticker SymbolCRMD
IPO dateMar 25, 2010
CEOTodisco (Joseph)
Company Executives of CorMedix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
87.65K
-40000.00%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
+69686.00%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
--
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
+13333.00%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
--
Mr. Myron M. Kaplan, J.D.
Mr. Myron M. Kaplan, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
302.20K
--
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
87.65K
-40000.00%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
69.69K
+69686.00%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
23.47K
--
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
13.33K
+13333.00%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
104.28M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.40%
Deep Track Capital LP
6.29%
Abdalkader (Shaibatalhamd Aymen)
5.84%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
Other
72.03%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.40%
Deep Track Capital LP
6.29%
Abdalkader (Shaibatalhamd Aymen)
5.84%
The Vanguard Group, Inc.
5.03%
Marshall Wace LLP
4.41%
Other
72.03%
Shareholder Types
Shareholders
Proportion
Investment Advisor
26.64%
Hedge Fund
16.79%
Investment Advisor/Hedge Fund
15.24%
Individual Investor
6.94%
Research Firm
2.04%
Pension Fund
1.09%
Bank and Trust
0.33%
Insurance Company
0.03%
Venture Capital
0.03%
Other
30.87%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
345
48.63M
61.72%
+3.95M
2025Q3
340
43.85M
56.33%
+8.67M
2025Q2
304
34.76M
43.08%
+9.67M
2025Q1
267
24.95M
43.35%
-4.41M
2024Q4
241
23.99M
39.87%
+4.76M
2024Q3
216
19.17M
36.31%
+1.94M
2024Q2
207
17.23M
38.40%
-272.84K
2024Q1
207
17.37M
41.54%
-5.46M
2023Q4
207
18.82M
39.64%
+838.41K
2023Q3
199
17.96M
39.30%
-1.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.04M
6.4%
+248.22K
+5.18%
Sep 30, 2025
Deep Track Capital LP
4.96M
6.29%
+4.46M
+891.10%
Nov 21, 2025
Abdalkader (Shaibatalhamd Aymen)
4.65M
6.22%
+4.65M
--
Aug 08, 2025
The Vanguard Group, Inc.
3.96M
5.03%
-347.89K
-8.07%
Sep 30, 2025
Marshall Wace LLP
3.47M
4.41%
+893.52K
+34.63%
Sep 30, 2025
Deerfield Management Company, L.P.
3.32M
4.22%
+3.32M
--
Sep 30, 2025
State Street Investment Management (US)
1.84M
2.33%
+233.97K
+14.61%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.81M
2.3%
+213.45K
+13.37%
Sep 30, 2025
Citadel Advisors LLC
1.72M
2.18%
+2.87K
+0.17%
Sep 30, 2025
Alyeska Investment Group, L.P.
1.26M
1.6%
+512.98K
+68.40%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
2.01%
Invesco Biotechnology & Genome ETF
1.87%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.52%
VictoryShares Small Cap Free Cash Flow ETF
0.79%
First Trust Active Factor Small Cap ETF
0.3%
Janus Henderson Small Cap Growth Alpha ETF
0.25%
ALPS Barron's 400 ETF
0.21%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.19%
Vanguard US Multifactor ETF
0.16%
iShares Micro-Cap ETF
0.15%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.01%
Invesco Biotechnology & Genome ETF
Proportion1.87%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.52%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.79%
First Trust Active Factor Small Cap ETF
Proportion0.3%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0.25%
ALPS Barron's 400 ETF
Proportion0.21%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0.19%
Vanguard US Multifactor ETF
Proportion0.16%
iShares Micro-Cap ETF
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of CorMedix Inc?
The top five shareholders of CorMedix Inc are:
BlackRock Institutional Trust Company, N.A. holds 5.04M shares, accounting for 6.40% of the total shares.
Deep Track Capital LP holds 4.96M shares, accounting for 6.29% of the total shares.
Abdalkader (Shaibatalhamd Aymen) holds 4.65M shares, accounting for 6.22% of the total shares.
The Vanguard Group, Inc. holds 3.96M shares, accounting for 5.03% of the total shares.
Marshall Wace LLP holds 3.47M shares, accounting for 4.41% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.04M shares, accounting for 6.40% of the total shares.
Deep Track Capital LP holds 4.96M shares, accounting for 6.29% of the total shares.
Abdalkader (Shaibatalhamd Aymen) holds 4.65M shares, accounting for 6.22% of the total shares.
The Vanguard Group, Inc. holds 3.96M shares, accounting for 5.03% of the total shares.
Marshall Wace LLP holds 3.47M shares, accounting for 4.41% of the total shares.
What are the top three shareholder types of CorMedix Inc?
The top three shareholder types of CorMedix Inc are:
BlackRock Institutional Trust Company, N.A.
Deep Track Capital LP
Abdalkader (Shaibatalhamd Aymen)
BlackRock Institutional Trust Company, N.A.
Deep Track Capital LP
Abdalkader (Shaibatalhamd Aymen)
How many institutions hold shares of CorMedix Inc (CRMD)?
As of 2025Q4, 345 institutions hold shares of CorMedix Inc, with a combined market value of approximately 48.63M, accounting for 61.72% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 5.39%.
What is the biggest source of revenue for CorMedix Inc?
In FY2025Q3, the -- business generated the highest revenue for CorMedix Inc, amounting to -- and accounting for --% of total revenue.
